Home » Boehringer-Ingelheim Completes Purchase of Amgen Fremont Facility
Boehringer-Ingelheim Completes Purchase of Amgen Fremont Facility
Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California (USA). This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site. The state-of-the-art facility currently employs more than 300 employees and consists of more than 200,000 square feet for laboratories, manufacturing and process development suitable for clinical and market supplies. The purchase agreement was signed in January 2011. The companies agreed not to disclose details of the purchase price.
"Presence in Fremont, CA aligns with our growth strategy in several ways," said Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim GmbH. "The strategic decision to have a state–of-the-art contract manufacturing facility in the U.S. Bay Area biotechnology cluster will give Boehringer Ingelheim a greater opportunity to serve current and future customers. In addition the technological expertise present at Fremont will complement our goal to further increase Boehringer Ingelheim's world leading position in the process development and manufacture of Biopharmaceuticals."
As a fully integrated manufacturing site, the Fremont site complements the existing capabilities and technology found across the existing Boehringer Ingelheim biopharma network located in Biberach/Germany and Vienna/Austria.
Boehringer Ingelheim has been a contract manufacturer for Amgen for ten years and will continue to support Amgen's delivery of safe and effective medicines to patients around the world. "We look forward to our continued contract manufacturing partnership with Amgen," said Simon Sturge.
The Boehringer Ingelheim contract manufacturing portfolio includes sixteen licensed biopharmaceuticals manufactured in globally licensed multi-product facilities, a growing pipeline of New Biological Entities (NBEs), and a growth strategy in the Contract Manufacturing Business (CMB). Boehringer Ingelheim's objective is to remain a leader in Contract Manufacturing as an industry benchmark for operational excellence including technical expertise and state-of-the-art technology.
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »